Loading organizations...
Pacira BioSciences, Inc. develops and commercializes pharmaceutical products for non-opioid pain management and regenerative health. Utilizing its proprietary pMVL drug delivery technology, the company creates precise, extended-release therapies. This approach offers patients sustained pain relief in post-surgical and acute settings, providing vital alternatives to traditional methods.
Established in 2006 as 21st Century BioPharmaceuticals, Inc., the company's founding is attributed to Joseph W. Dong, PhD. Pacira’s core insight was the urgent need for effective, non-addictive pain management options, driving innovation. This led to pioneering pharmaceutical solutions mitigating addiction risks while addressing patient pain.
Pacira's portfolio serves patients requiring robust pain control without opioid reliance. The company aims to transform global pain management through continuous innovation in non-opioid treatments. Its long-term vision focuses on optimizing patient care and satisfaction, enhancing health outcomes and contributing to public health goals for safer pain relief.
Key people at Pacira Pharmaceuticals, Inc..
Pacira BioSciences, Inc. (formerly Pacira Pharmaceuticals) is a specialty pharmaceutical company pioneering non-opioid pain management solutions, primarily through its flagship product EXPAREL (bupivacaine liposome injectable suspension), a long-acting local anesthetic providing pain relief for up to 72 hours post-surgery.[1][3][4] It serves surgical specialties like orthopedic, general, and plastic surgery, addressing the opioid crisis by offering alternatives that reduce opioid reliance for millions of patients.[3][4] The company projects $730–750 million in total revenue for fiscal 2025, driven by EXPAREL growth, with an expanding pipeline including gene therapies for osteoarthritis and chronic pain.[1][3]
Pacira solves acute and chronic pain challenges using proprietary pMVL (multivesicular liposome) drug delivery technology for extended-release formulations, alongside innovations like ZILRETTA and in-licensed assets.[1][3] Recent momentum includes accelerated EXPAREL volume growth, improved payer coverage for NOPAIN, a J&J MedTech partnership for ZILRETTA, and pipeline progress like completing Phase 2 enrollment for PCRX-201 (enekinragene inzadenovec) in November 2025.[1][3]
Pacira traces its roots to predecessors DepoTech and SkyePharma, with the company formally founded in 2006 (though some sources cite 1997 as the foundational year for its technology base).[1][2][3] It emerged focused on postsurgical pain management amid rising opioid concerns, leveraging advanced drug delivery systems to create non-opioid alternatives.[1][2][3] Early traction came from developing EXPAREL, which established Pacira as a leader in targeted pain relief, building on over two decades of innovation in the space.[1][4]
Pivotal moments include rebranding to Pacira BioSciences to reflect its evolution into a broader biopharma player, the February 2025 acquisition of GQ Bio Therapeutics for gene therapy platforms, and in-licensing AMT-143 as a long-acting analgesic.[1][3] These steps marked a shift from single-product reliance to a diversified pipeline, humanizing its mission to transform patient lives beyond opioids.[4]
Pacira rides the non-opioid pain management trend, fueled by the U.S. opioid crisis and regulatory pushes for alternatives, transforming surgical care across specialties.[1][3][4] Timing is ideal amid post-pandemic surgery backlogs and payer incentives for opioid-sparing therapies, with EXPAREL's market penetration signaling strong demand.[1][3] Favorable forces include clinical data supporting long-acting locals, gene therapy advancements, and partnerships like J&J's for ZILRETTA, enhancing ecosystem access.[3]
It influences biotech by pioneering drug delivery innovations, inspiring regenerative health shifts, and leading musculoskeletal pain solutions, potentially setting standards for decades via genetic medicines.[1][4]
Pacira's trajectory hinges on pipeline execution, with PCRX-201 Phase 2 data and next-gen assets like AMT-143 poised to diversify beyond EXPAREL amid 2025 revenue strength.[1][3] Trends like gene therapies for osteoarthritis, expanded payer coverage, and manufacturing gains will shape growth, targeting market leadership in non-opioid innovation.[1][3] Influence may evolve through high-risk bets paying off, solidifying its role as a pain management transformative force—echoing its founding mission to redefine relief without opioids.[4]
Key people at Pacira Pharmaceuticals, Inc..
